Physician profile
John E Shuman
NPI 1104808625
$2,039.61
in general payments reported to CMS, 2019-2025
14 companies · $670 in 2025
The $670 reported for 2025 was more than what 85% of Surgical providers received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $44.61 · 2022: $44.17 · 2023: $539 · 2024: $741 · 2025: $670.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,951.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,950.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avita Medical Americas, LLC | $676.98 | 2023-2025 | Recell, Permeaderm, Cohealyx |
| Polynovo North America LLC | $294.57 | 2022-2025 | Novosorb Btm |
| Urgo Medical North America, LLC | $212.13 | 2024 | Vashe Wound Solution 250 Ml (8.5 Fl Oz) Flip Top Cap |
| Exact Sciences Corporation | $125.00 | 2023 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $122.78 | 2025 | |
| Glaxosmithkline, LLC. | $103.83 | 2025 | Blujepa |
| Convatec INC. | $95.50 | 2023 | |
| Scpharmaceuticals INC. | $93.42 | 2024 | |
| Integra Lifesciences Corporation | $93.22 | 2024-2025 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Smith+Nephew, INC. | $79.33 | 2021-2025 | Collagenase Santyl |
| Janssen Scientific Affairs, LLC | $74.14 | 2023 | Xarelto |
| Abbvie INC. | $25.90 | 2023 | |
| Allergan, INC. | $22.86 | 2022 | |
| Solventum Corporation | $19.95 | 2024 | V.A.C.Instill |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Shuman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.